Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 391

1.

Mirtazapine in major depression with comorbid generalized anxiety disorder.

Goodnick PJ, Puig A, DeVane CL, Freund BV.

J Clin Psychiatry. 1999 Jul;60(7):446-8.

PMID:
10453798
[PubMed - indexed for MEDLINE]
2.

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT.

Int Clin Psychopharmacol. 1999 Nov;14(6):329-37.

PMID:
10565799
[PubMed - indexed for MEDLINE]
3.

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.

Silverstone PH, Salinas E.

J Clin Psychiatry. 2001 Jul;62(7):523-9.

PMID:
11488362
[PubMed - indexed for MEDLINE]
4.

Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.

Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.

J Clin Psychiatry. 1999 Sep;60(9):580-3.

PMID:
10520975
[PubMed - indexed for MEDLINE]
5.

Care of depressed patients with anxiety symptoms.

Nutt DJ.

J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. Review.

PMID:
10446738
[PubMed - indexed for MEDLINE]
6.

Mirtazapine compared with paroxetine in major depression.

Benkert O, Szegedi A, Kohnen R.

J Clin Psychiatry. 2000 Sep;61(9):656-63.

PMID:
11030486
[PubMed - indexed for MEDLINE]
7.

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.

Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ; Comparative Efficacy Antidepressants Study Group.

CNS Drugs. 2005;19(2):137-46.

PMID:
15697327
[PubMed - indexed for MEDLINE]
8.

Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

Pallanti S, Quercioli L, Bruscoli M.

J Clin Psychiatry. 2004 Oct;65(10):1394-9.

PMID:
15491244
[PubMed - indexed for MEDLINE]
9.

An open-label trial of nefazodone in high comorbidity panic disorder.

DeMartinis NA, Schweizer E, Rickels K.

J Clin Psychiatry. 1996 Jun;57(6):245-8.

PMID:
8666561
[PubMed - indexed for MEDLINE]
10.

Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.

Yoon SJ, Pae CU, Kim DJ, Namkoong K, Lee E, Oh DY, Lee YS, Shin DH, Jeong YC, Kim JH, Choi SB, Hwang IB, Shin YC, Cho SN, Lee HK, Lee CT.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1196-201. Epub 2006 Apr 19.

PMID:
16624467
[PubMed - indexed for MEDLINE]
11.

Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study.

Varia I, Venkataraman S, Hellegers C, Gersing K, Doraiswamy PM.

Psychopharmacol Bull. 2007;40(1):47-56.

PMID:
17285095
[PubMed - indexed for MEDLINE]
12.

Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.

Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):175-84.

PMID:
15319015
[PubMed - indexed for MEDLINE]
13.

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.

Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O.

J Clin Psychiatry. 2003 Apr;64(4):413-20.

PMID:
12716243
[PubMed - indexed for MEDLINE]
14.

A risk-benefit assessment of mirtazapine in the treatment of depression.

Kasper S, Praschak-Rieder N, Tauscher J, Wolf R.

Drug Saf. 1997 Oct;17(4):251-64. Review. Erratum in: Drug Saf 1998 Feb;18(2):123.

PMID:
9352961
[PubMed - indexed for MEDLINE]
15.

Mirtazapine: other indications.

Falkai P.

J Clin Psychiatry. 1999;60 Suppl 17:36-40; discussion 46-8. Review.

PMID:
10446741
[PubMed - indexed for MEDLINE]
16.

Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.

Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G, Mezzano D, Cicconetti A, Penna L, Salerno RM, Ferro FM.

J Psychopharmacol. 2005 Sep;19(5):483-7.

PMID:
16166185
[PubMed - indexed for MEDLINE]
17.

Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.

J Psychopharmacol. 2002 Sep;16(3):215-9.

PMID:
12236627
[PubMed - indexed for MEDLINE]
18.
19.

Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.

Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA.

Biol Psychiatry. 2000 Jul 1;48(1):75-8.

PMID:
10913511
[PubMed - indexed for MEDLINE]
20.

Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.

Pasquini M, Biondi M, Costantini A, Cairoli F, Ferrarese G, Picardi A, Sternberg C.

Depress Anxiety. 2006;23(7):441-8.

PMID:
16841345
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk